TY - JOUR T1 - A demonstration of cone function plasticity after gene therapy in achromatopsia JF - medRxiv DO - 10.1101/2020.12.16.20246710 SP - 2020.12.16.20246710 AU - Mahtab Farahbakhsh AU - Elaine J. Anderson AU - Andy Rider AU - John A. Greenwood AU - Nashila Hirji AU - Serena Zaman AU - Pete R. Jones AU - D. Samuel Schwarzkopf AU - Geraint Rees AU - Michel Michaelides AU - Tessa M. Dekker Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/26/2020.12.16.20246710.abstract N2 - Recent advances in regenerative therapy have placed the treatment of many previously incurable eye diseases within arms-reach (Ciulla et al., 2020). Achromatopsia (ACHM) is a severe monogenic heritable retinal disease that disrupts cone function from gestation, leaving patients with complete colour blindness, low acuity, photosensitivity, and nystagmus (Hirji, Aboshiha, et al., 2018). In non-primate animal models of ACHM, retinal gene-replacement therapy has successfully induced cone function in the young (Alexander et al., 2007; Carvalho et al., 2011), but it was yet to be determined if and when these therapies could effectively impact cone-mediated pathways in the human brain. Here we demonstrate in children with ACHM that gene therapy can yield substantial improvement in cone-mediated vision, via cascading effects on signal transmission from retina to cortex. To measure the effects of treatment in children with ACHM (CNGA3- and CNGB3-associated, all aged 10+ years), we developed novel visual stimuli, calibrated to selectively activate cone photoreceptors. We used these in behavioural psychophysics and functional MRI with population receptive field mapping, pre- and post-treatment. The results of treatment, contextualized against data from 12 untreated ACHM patients and 25 normal-sighted, revealed that six months post-therapy, two patients displayed novel responses to our cone-selective stimuli in the visual cortex, with a retinotopic organisation characteristic of normal-sighted individuals, not present in untreated ACHM. This was paired with significant improvement in cone-mediated perception specific to the treated eye, and self-reports of improved vision. Two other patients did not show a post-treatment effect, potentially reflecting individual differences in therapeutic outcome. Together, these data show that gene replacement therapy in humans with ACHM can activate dormant cone pathways despite long-term deprivation. This offers great promise for regenerative therapies, and their ability to trigger the neural plasticity needed to cure congenital vision loss in human patients.Competing Interest StatementMM declares financial interest in MeiraGtxClinical TrialPatients were enrolled in clinical trials NCT03758404 and NCT03001310. Data collection for this MRI study had stand-alone ethics approval, from the national ethics committee for patients (#MICM1007) and the UCL ethics committee for normal sighted control participants (#4846/001).Funding StatementThe research was supported by grants from the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, the European Social Research Council (#ES/N000838/1); MeiraGTx, Retina UK, Moorfields Eye Hospital Special Trustees, Moorfields Eye Charity (R160035A, R190029A, R180004A), Foundation Fighting Blindness (USA) and The Wellcome Trust (099173/Z/12/Z, 100227), Ardalan Family Scholarship, the Persia Educational Foundation Maryam Mirzakhani Scholarship; and the Sir Richard Stapley Educational Trust (#313812). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval for study protocol was approved from the UCL research ethics committee and the NHS Research Ethics Committee (reference #4846/001 and #MICM1007, respectively)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data is currently made available. ER -